Fluoxetine to Prevent Relapse and Enhance Psychological Recovery in Women With Anorexia Nervosa

Completed · Phase 4 · Has a placebo group

Conditions studied: Anorexia Nervosa, Eating Disorders

In brief

This study will evaluate the effectiveness of fluoxetine versus placebo in reducing the rate of relapse of anorexia nervosa (AN) and enhancing the psychosocial and behavioral recovery of people who have been treated for AN.

Key facts

Study ID

NCT00288574

Run by

New York State Psychiatric Institute

People needed

93

Starts

2000-01-01

Expected to finish

2005-05-01

Last updated by the study team

2017-12-13

Who can join

Age: 16 and older, up to 45. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Meets DSM-IV criteria for anorexia nervosa (except the requirement for amenorrhea)
• Successfully completed treatment at one of the study sites in an inpatient or day-program setting immediately prior to study entry (BMI remained at least 19 kg/m2 for two weeks)

You may not qualify if…

• Currently taking any medications other than occasional lorazepam or zopiclone for anxiety or sleep disturbance
• Previous serious adverse reactions to fluoxetine (e.g., allergy)
• Currently at risk for suicide
• Any medical condition requiring treatment with other psychotropic medication (except the occasional use of anti-anxiety medication)
• Pregnant
• Any serious medical illness besides the eating disorder
• History of continuous illness (at a low weight with no periods of remission or return to normal functioning for more than 15 years)

Where it is running

• New York State Psychiatric Institute/Columbia University Medical Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.